肝脏对比增强超声(CEUS)指南与良好临床实践建议——2020年更新版——WFUMB与EFSUMB、AFSUMB、AIUM及FLAUS合作制定
该文件为肝脏CEUS推荐意见的第四次迭代更新,由EFSUMB于2004年首次发起,本次由WFUMB与EFSUMB、AFSUMB、AIUM及FLAUS合作制定。2012版指南需更新,因既往未精确描述各对比剂差异、未清晰说明对比时相及操作差异,且各对比剂新证据增多。更新还纳入对比剂最新进展,包括美国FDA批准及广泛亚洲经验,以形成真正的国际视角。
要点
- 2012版指南需更新,因既往未精确描述各对比剂差异,未清晰说明对比时相及操作差异。
- 更新纳入对比剂最新进展,包括美国FDA批准及广泛亚洲经验,形成国际视角。
- 指南旨在建立肝脏应用中使用和给予超声对比剂(UCA)的国际标准方案。
核心结论
- 这些指南与建议提供使用超声对比剂(UCA)的一般性建议,旨在建立肝脏应用中使用和给予UCA的国际标准方案,以改善患者管理。
研究设计与样本
- 制定机构为WFUMB与EFSUMB、AFSUMB、AIUM及FLAUS合作;文件为肝脏CEUS推荐意见的第四次迭代更新,由EFSUMB于2004年首次发起;原文未报告证据分级方法与纳入文献范围。
局限性
- 2012版指南需更新,因既往未精确描述各对比剂差异,未清晰说明对比时相及操作差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The present, updated document describes the fourth iteration of recommendations for the hepatic use of contrast enhanced ultrasound (CEUS), first initiated in 2004 by the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB). The previous updated editions of the guidelines reflected changes in the available contrast agents and updated the guidelines not only for hepatic but also for non-hepatic applications.The 2012 guideline requires updating as previously the differences of the contrast agents were not precisely described and the differences in contrast phases as well as handling were not clearly indicated. In addition, more evidence has been published for all contrast agents. The update also reflects the most recent developments in contrast agents, including the United States Food and Drug Administration (FDA) approval as well as the extensive Asian experience, to produce a truly international perspective.These guidelines and recommendations provide general advice on the use of ultrasound contrast agents (UCA) and are intended to create standard protocols for the use and administration of UCA in liver applications on an international basis to improve the management of patients.
引用
- Dietrich CF, Nolsøe CP, Barr RG, et al. Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the Liver - Update 2020 - WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall Med. 2020. PMID: 32707595. doi:10.1055/a-1177-0530
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。